Valneva (VALN) Competitors $7.22 -0.13 (-1.77%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. RARE, MIRM, CPRX, AMRX, IBRX, BHC, APLS, XENE, AGIO, and BEAMShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Ultragenyx Pharmaceutical (RARE), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Bausch Health Cos (BHC), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Agios Pharmaceuticals (AGIO), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors Ultragenyx Pharmaceutical Mirum Pharmaceuticals Catalyst Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Bausch Health Cos Apellis Pharmaceuticals Xenon Pharmaceuticals Agios Pharmaceuticals Beam Therapeutics Ultragenyx Pharmaceutical (NASDAQ:RARE) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations. Which has more risk and volatility, RARE or VALN? Ultragenyx Pharmaceutical has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Do analysts rate RARE or VALN? Ultragenyx Pharmaceutical presently has a consensus price target of $83.08, indicating a potential upside of 192.11%. Valneva has a consensus price target of $15.50, indicating a potential upside of 114.68%. Given Ultragenyx Pharmaceutical's higher probable upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RARE or VALN more profitable? Valneva has a net margin of -43.08% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Valneva's return on equity of -43.05% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Valneva -43.08%-43.05%-16.23% Which has preferable earnings & valuation, RARE or VALN? Valneva has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Valneva is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M4.80-$569.18M-$5.88-4.84Valneva$183.52M3.35-$13.25M-$1.19-6.07 Does the media favor RARE or VALN? In the previous week, Ultragenyx Pharmaceutical had 20 more articles in the media than Valneva. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 2 mentions for Valneva. Ultragenyx Pharmaceutical's average media sentiment score of 0.84 beat Valneva's score of 0.70 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 7 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in RARE or VALN? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryUltragenyx Pharmaceutical and Valneva tied by winning 8 of the 16 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$614.24M$10.46B$5.53B$9.37BDividend YieldN/A2.02%4.74%4.12%P/E Ratio-6.0718.7328.8523.79Price / Sales3.3529.30440.8796.30Price / Cash73.8821.9835.0757.18Price / Book3.003.478.255.54Net Income-$13.25M$234.77M$3.25B$259.88M7 Day Performance-5.99%-4.82%-3.73%-4.67%1 Month Performance24.91%1.80%4.28%4.40%1 Year Performance2.41%-12.51%25.84%17.91% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.7103 of 5 stars$7.22-1.8%$15.50+114.7%+2.4%$614.24M$183.52M-6.07700RAREUltragenyx Pharmaceutical4.4797 of 5 stars$27.61+1.0%$82.57+199.1%-35.6%$2.58B$560.23M-4.701,294Analyst RevisionMIRMMirum Pharmaceuticals3.7141 of 5 stars$51.49-0.7%$65.50+27.2%+29.6%$2.57B$379.25M-31.98140News CoveragePositive NewsUpcoming EarningsCPRXCatalyst Pharmaceuticals4.8968 of 5 stars$20.80-0.8%$32.83+57.9%+24.7%$2.56B$491.73M13.2580Positive NewsUpcoming EarningsAMRXAmneal Pharmaceuticals3.5371 of 5 stars$8.17+1.4%$11.60+42.0%+9.1%$2.53B$2.79B-204.208,100News CoverageIBRXImmunityBio2.2315 of 5 stars$2.65-7.3%$12.25+362.3%-50.5%$2.52B$14.74M-4.57590News CoverageGap DownBHCBausch Health Cos4.6418 of 5 stars$6.88+1.6%$7.38+7.2%-6.4%$2.51B$9.63B-62.5520,700News CoverageEarnings ReportAnalyst UpgradeAPLSApellis Pharmaceuticals4.6941 of 5 stars$18.75-4.3%$40.00+113.3%-36.3%$2.46B$781.37M-10.47770Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals2.9417 of 5 stars$30.97+2.2%$54.82+77.0%-30.3%$2.33B$9.43M-9.59210News CoveragePositive NewsShort Interest ↑AGIOAgios Pharmaceuticals4.0149 of 5 stars$37.20-7.0%$56.33+51.4%-21.3%$2.32B$36.50M3.31390News CoverageEarnings ReportBEAMBeam Therapeutics2.5948 of 5 stars$20.83-4.1%$48.75+134.0%-37.9%$2.18B$63.52M-4.52510Upcoming EarningsInsider TradeGap Down Related Companies and Tools Related Companies RARE Alternatives MIRM Alternatives CPRX Alternatives AMRX Alternatives IBRX Alternatives BHC Alternatives APLS Alternatives XENE Alternatives AGIO Alternatives BEAM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VALN Stock Alerts